Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Lanifibranor (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2018 According to an Inventiva Pharma media release, the first of 64 patients for this study has been enrolled in August 2018.
- 30 Aug 2018 Status changed from not yet recruiting to recruiting, according to an Inventiva Pharma media release.